{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Dry powder inhaler", "Leucine", "Levofloxacin", "Metal salts", "Particle engineering", "Spray drying"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31808069", "DateCompleted": {"Year": "2021", "Month": "02", "Day": "26"}, "DateRevised": {"Year": "2021", "Month": "02", "Day": "26"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "12", "Day": "05"}], "Language": ["eng"], "ELocationID": ["10.1007/s40199-019-00317-9"], "Journal": {"ISSN": "2008-2231", "JournalIssue": {"Volume": "28", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jun"}}, "Title": "Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences", "ISOAbbreviation": "Daru"}, "ArticleTitle": "The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.", "Pagination": {"StartPage": "75", "EndPage": "85", "MedlinePgn": "75-85"}, "Abstract": {"AbstractText": ["Metal salts are used in formulation of dry powder inhalers (DPIs) for different purposes. Recently the role of these salts in production of small, dense but highly dispersible particles has emerged. In this study the effect of some such salts on dispersibility and respirability of spray dried levofloxacin formulations was evaluated in normal and reduced inhalation air flow or by increasing powder filling in capsules.", "levofloxacin was co-spray dried with different concentrations of common metal chlorides (NaCl, KCl, CaCl<sub>2</sub> and MgCl<sub>2</sub>) either with or without leucine as dispersibility enhancer. Particle size, moisture, morphology, triboelectrification tendency and fine particle fraction (FPF) of resulting powders were evaluated. In addition, the effect of these salts and leucine on dispersibility of resulting powders in reduced air flow rate and increased capsule filling mass were evaluated.", "Presence of higher tested concentrations of divalent cations increased water content, and reduced FPF significantly. Addition of leucine reduced water content and electrostatic charge, increased particle size and FPF and improved spray drying yield significantly. Lower concentrations of salts did not affect FPF of leucine containing powders significantly, but presence of 2.5% NaCl or MgCl<sub>2</sub> preserved the dispersibility in higher capsule fillings. A 2.5% concentration of NaCl in such formulations preserved dispersibility in lower air flows.", "Higher amounts of divalent salts increases triboelectrification and moisture absorption, and reduces FPF. Lower concentrations of NaCl could not improve FPF of leucine containing formulations significantly, but preserves dispersibility in low air flows and high capsule fillings. Graphical abstract."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Barazesh", "ForeName": "Ahmadreza", "Initials": "A"}, {"Identifier": ["0000-0002-3620-0819"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Aerosol Research Laboratory, Department of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. gilani@tums.ac.ir."}, {"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran. gilani@tums.ac.ir."}], "LastName": "Gilani", "ForeName": "Kambiz", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Rouini", "ForeName": "Mohammadreza", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "XRD Research Laboratory, School of Science, University of Tehran, Tehran, Iran."}], "LastName": "Barghi", "ForeName": "Mohammad Ali", "Initials": "MA"}], "GrantList": [{"GrantID": "94-01-33-28742", "Agency": "Tehran University of Medical Sciences and Health Services", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Daru", "NlmUniqueID": "101125969", "ISSNLinking": "1560-8115"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Aerosols"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Bacterial Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Chlorides"}, {"RegistryNumber": "0", "NameOfSubstance": "Metals"}, {"RegistryNumber": "0", "NameOfSubstance": "Powders"}, {"RegistryNumber": "6GNT3Y5LMF", "NameOfSubstance": "Levofloxacin"}, {"RegistryNumber": "GMW67QNF9C", "NameOfSubstance": "Leucine"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aerosols"}, {"QualifierName": ["chemistry"], "DescriptorName": "Anti-Bacterial Agents"}, {"QualifierName": [], "DescriptorName": "Chemistry, Pharmaceutical"}, {"QualifierName": ["chemistry"], "DescriptorName": "Chlorides"}, {"QualifierName": [], "DescriptorName": "Dry Powder Inhalers"}, {"QualifierName": ["chemistry"], "DescriptorName": "Leucine"}, {"QualifierName": ["chemistry"], "DescriptorName": "Levofloxacin"}, {"QualifierName": ["chemistry"], "DescriptorName": "Metals"}, {"QualifierName": [], "DescriptorName": "Particle Size"}, {"QualifierName": [], "DescriptorName": "Powders"}, {"QualifierName": [], "DescriptorName": "Spray Drying"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized. Dose-Escalation Study Clin Ther. 2013;35:1571\u20131581. doi: 10.1016/j.clinthera.2013.08.003.", "ArticleIdList": ["10.1016/j.clinthera.2013.08.003", "24054830"]}, {"Citation": "Dudley MN, Loutit J, Griffith DC. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol. 2008;19:637\u2013643. doi: 10.1016/j.copbio.2008.11.002.", "ArticleIdList": ["10.1016/j.copbio.2008.11.002", "19036576"]}, {"Citation": "Zhou QT, Leung SSY, Tang P, Parumasivam T, Loh ZH, Chan HK. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv Drug Deliv Rev. 2015;85:83\u201399. doi: 10.1016/j.addr.2014.10.022.", "ArticleIdList": ["10.1016/j.addr.2014.10.022", "25451137"]}, {"Citation": "Flume PA, O\u2019Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2007;176:957\u2013969. doi: 10.1164/rccm.200705-664OC.", "ArticleIdList": ["10.1164/rccm.200705-664OC", "17761616"]}, {"Citation": "Tiddens HAWM, Bos AC, Mouton JW, Devadason S, Janssens HM. Inhaled antibiotics: dry or wet? Eur Respir J. 2014;44:1308\u20131318. doi: 10.1183/09031936.00090314.", "ArticleIdList": ["10.1183/09031936.00090314", "25323242"]}, {"Citation": "Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2006;41:656\u2013665. doi: 10.1002/ppul.20429.", "ArticleIdList": ["10.1002/ppul.20429", "16703579"]}, {"Citation": "Geller DE, Flume PA, Griffith DC, Morgan E, White D, Loutit JS, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011;55:2636\u20132640. doi: 10.1128/AAC.01744-10.", "ArticleIdList": ["10.1128/AAC.01744-10", "PMC3101414", "21444699"]}, {"Citation": "d\u2019Angelo I, Conte C, La Rotonda MI, Miro A, Quaglia F, Ungaro F. Improving the efficacy of inhaled drugs in cystic fibrosis: challenges and emerging drug delivery strategies. Adv Drug Deliv Rev. 2014;75:92\u2013111. doi: 10.1016/j.addr.2014.05.008.", "ArticleIdList": ["10.1016/j.addr.2014.05.008", "24842473"]}, {"Citation": "Ting L, Aksenov S, Bhansali SG, Ramakrishna R, Tang P, Geller DE. Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients. CPT Pharmacometrics Syst Pharmacol. 2014;3:e99. doi: 10.1038/psp.2013.76.", "ArticleIdList": ["10.1038/psp.2013.76", "PMC3944114", "24522146"]}, {"Citation": "Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care. 2009;54:754\u2013768. doi: 10.4187/002013209790983250.", "ArticleIdList": ["10.4187/002013209790983250", "19467162"]}, {"Citation": "Manzanedo D, Brande M, Kramer SR, Yee LW, Dehaan WH, Clarke RW, et al. Formulation characterization of a novel levofloxacin pulmonary dry powder drug delivery technology. Respir. Drug Deliv. 2012;2012:713\u2013716."}, {"Citation": "Weers JG, Bell J, Chan H-K, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary Formulations: What Remains to be Done? J Aerosol Med Pulm Drug Deliv. 2010;23:S-5\u2013S-23. doi: 10.1089/jamp.2010.0838.", "ArticleIdList": ["10.1089/jamp.2010.0838", "21133800"]}, {"Citation": "Pilcer G, De Bueger V, Traina K, Traore H, Sebti T, Vanderbist F, et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm. 2013;451:112\u2013120. doi: 10.1016/j.ijpharm.2013.04.069.", "ArticleIdList": ["10.1016/j.ijpharm.2013.04.069", "23643509"]}, {"Citation": "Tian G, Longest PW, Li X, Hindle M. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv. 2013;26:248\u2013265. doi: 10.1089/jamp.2012.0997.", "ArticleIdList": ["10.1089/jamp.2012.0997", "PMC3826577", "23286828"]}, {"Citation": "Healy AM, Amaro MI, Paluch KJ, Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv Drug Deliv Rev. 2014;75:32\u201352. doi: 10.1016/j.addr.2014.04.005.", "ArticleIdList": ["10.1016/j.addr.2014.04.005", "24735676"]}, {"Citation": "Srinivasan G, Shetty A. Advancements in dry powder inhaler. Asian J Pharm Clin Res. 2017;10:8. doi: 10.22159/ajpcr.2017.v10i2.14282.", "ArticleIdList": ["10.22159/ajpcr.2017.v10i2.14282"]}, {"Citation": "Lipp MM, Sung JC. Cationic dry powders. US Patent 9,744,130, 2017."}, {"Citation": "Barazesh A, Gilani K, Rouini M, Barghi MA. Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin. Eur J Pharm Sci. 2018;118:13\u201323. doi: 10.1016/j.ejps.2018.03.002.", "ArticleIdList": ["10.1016/j.ejps.2018.03.002", "29505814"]}, {"Citation": "Kaialy W, Hussain T, Alhalaweh A, Nokhodchi A. Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres. Pharm Res. 2014;31:60\u201376. doi: 10.1007/s11095-013-1132-2.", "ArticleIdList": ["10.1007/s11095-013-1132-2", "23918220"]}, {"Citation": "Kho K, Hadinoto K. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Colloids Surfaces A Physicochem Eng Asp. 2010;359:71\u201381. doi: 10.1016/j.colsurfa.2010.01.066.", "ArticleIdList": ["10.1016/j.colsurfa.2010.01.066"]}, {"Citation": "Maleque M, Hasan MR, Hossen F, Safi S. Development and validation of a simple UV spectrophotometric method for the determination of levofloxacin both in bulk and marketed dosage formulations. J Pharm Anal. 2012;2:454\u2013457. doi: 10.1016/j.jpha.2012.06.004.", "ArticleIdList": ["10.1016/j.jpha.2012.06.004", "PMC5760935", "29403782"]}, {"Citation": "Nichols SC, Brown DR, Smurthwaite M. New Concept for the Variable Flow Rate Andersen Cascade Impactor and Calibration Data. J Aerosol Med. 1998;11.", "ArticleIdList": ["10180726"]}, {"Citation": "Belotti S, Rossi A, Colombo P, Bettini R, Rekkas D, Politis S, Colombo G, Balducci AG, Buttini F. Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction. Int J Pharm. 2014;471:507\u2013515. doi: 10.1016/j.ijpharm.2014.05.055.", "ArticleIdList": ["10.1016/j.ijpharm.2014.05.055", "24886692"]}, {"Citation": "Albayrak C, Bar\u0131m G, Dag \u00d6. Effect of hygroscopicity of the metal salt on the formation and air stability of lyotropic liquid crystalline mesophases in hydrated salt\u2013surfactant systems. J Colloid Interface Sci. 2014;433:26\u201333. doi: 10.1016/j.jcis.2014.07.008.", "ArticleIdList": ["10.1016/j.jcis.2014.07.008", "25112909"]}, {"Citation": "Mickey AJ, Gonda I, Irwin WJ, FJT F. Effect of hydrophobic coating on the behavior of a hygroscopic aerosol powder in an environment of controlled temperature and relative humidity. J Pharm Sci. 1990.", "ArticleIdList": ["2292762"]}, {"Citation": "Yang X-F, Xu Y, Qu D-S, Li H-Y. The influence of amino acids on aztreonam spray-dried powders for inhalation. Asian J Pharm Sci. 2015;10:541\u2013548. doi: 10.1016/j.ajps.2015.08.002.", "ArticleIdList": ["10.1016/j.ajps.2015.08.002"]}, {"Citation": "Li L, Sun S, Parumasivam T, Denman JA, Gengenbach T, Tang P, Mao S, Chan HK. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders. Eur J Pharm Biopharm. 2016;102:132\u2013141. doi: 10.1016/j.ejpb.2016.02.010.", "ArticleIdList": ["10.1016/j.ejpb.2016.02.010", "26970252"]}, {"Citation": "Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25:999\u20131022. doi: 10.1007/s11095-007-9475-1.", "ArticleIdList": ["10.1007/s11095-007-9475-1", "PMC2292490", "18040761"]}, {"Citation": "Mangal S, Meiser F, Tan G, Gengenbach T, Denman J, Rowles MR, Larson I, Morton DA. Relationship between surface concentration of l-leucine and bulk powder properties in spray dried formulations. Eur J Pharm Biopharm. 2015;94:160\u2013169. doi: 10.1016/j.ejpb.2015.04.035.", "ArticleIdList": ["10.1016/j.ejpb.2015.04.035", "26007290"]}, {"Citation": "Feng AL, Boraey MA, Gwin MA, Finlay PR, Kuehl PJ, Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int J Pharm. 2011;409:156\u2013163. doi: 10.1016/j.ijpharm.2011.02.049.", "ArticleIdList": ["10.1016/j.ijpharm.2011.02.049", "21356284"]}, {"Citation": "Chen L, Okuda T, Lu X-Y, Chan H-K. Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev. 2016;100:102\u2013115. doi: 10.1016/j.addr.2016.01.002.", "ArticleIdList": ["10.1016/j.addr.2016.01.002", "26780404"]}, {"Citation": "Karner S, Anne UN. The impact of electrostatic charge in pharmaceutical powders with specific focus on inhalation-powders. J Aerosol Sci. 2011;42:428\u2013445. doi: 10.1016/j.jaerosci.2011.02.010.", "ArticleIdList": ["10.1016/j.jaerosci.2011.02.010"]}, {"Citation": "Murtomaa M, Savolainen M, Christiansen L, Rantanen J, Laine E, Yliruusi J. Static electrification of powders during spray drying. J Electrost. 2004;62:63\u201372. doi: 10.1016/j.elstat.2004.05.001.", "ArticleIdList": ["10.1016/j.elstat.2004.05.001"]}, {"Citation": "Price R, Young PM, Edge S, Staniforth JN. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int J Pharm. 2002.", "ArticleIdList": ["12270608"]}, {"Citation": "Lawlor CP, Tauber MK, Brogan JT, Zhu L, Currie DF, Trautman BG, et al. Levofloxacin dry powders engineered for efficient pulmonary delivery and stability. Respir Drug Deliv. 2014;2014:549\u2013552."}]}], "History": [{"Year": "2019", "Month": "8", "Day": "15"}, {"Year": "2019", "Month": "11", "Day": "13"}, {"Year": "2019", "Month": "12", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "2", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "5"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31808069", "PMC7214557", "10.1007/s40199-019-00317-9", "10.1007/s40199-019-00317-9"]}}]}